Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants.
J Infect
; 87(3): 282-285, 2023 09.
Article
in En
| MEDLINE
| ID: mdl-37451364
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hematologic Neoplasms
/
COVID-19
/
Antibodies, Monoclonal
Limits:
Humans
Language:
En
Journal:
J Infect
Year:
2023
Document type:
Article
Country of publication:
Reino Unido